Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
NB Private Equity Partners
2025 CMD: good returns from low-risk PE model
3rd Dec 2025
Real Estate Credit Investments (RECI)
Investor Day: opportunities aplenty
2nd Dec 2025
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
125: EIS and VC Basics: How venture capital exits work in EIS & VCTs | Kealan Doyle of Symvan Capital
Stay up-to-date with the latest research
Sign up to our newsletter
Register now for Wednesday 21 January 2026 at 12:30pm -
Event | Four distinct approaches to EIS investing: Tax Advantaged Online Forum
Life Sciences research
Life Sciences
Hardman & Co Healthcare Index
By
Dr Martin Hall
14 Jan 2021
Shield Therapeutics Plc
Life Sciences
Reassessing the US opportunity
By
Dr Martin Hall
06 Jan 2021
Stay up-to-date with the latest research
Sign up to our newsletter
Advanced Oncotherapy
Life Sciences
Leveraging the modularity of LIGHT
By
Dr Martin Hall
15 Dec 2020
Incanthera Ltd
Life Sciences
Solid progress since listing
By
Dr Martin Hall
08 Dec 2020
Arix Bioscience
Life Sciences
Artios attracts Merck KGaA in deal up to $7bn
By
Dr Martin Hall
07 Dec 2020
Arix Bioscience
Life Sciences
Hitting the jackpot
By
Dr Martin Hall
06 Nov 2020
Tissue Regenix
Life Sciences
Funded through to profitability
By
Dr Martin Hall
07 Oct 2020
Advanced Oncotherapy
Life Sciences
Progress towards commissioning of first LIGHT
By
Dr Martin Hall
07 Oct 2020
Diurnal Group Plc
Life Sciences
And then there were three
By
Dr Martin Hall
30 Sep 2020
Arix Bioscience
Life Sciences
Realising the valuation disconnect
By
Dr Martin Hall
21 Sep 2020
Shield Therapeutics Plc
Life Sciences
Optimism over US deal
By
Dr Martin Hall
18 Sep 2020
Prev
1
...
4
5
6
7
8
...
22
Next
